Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel.

[1]  M. Pinto,et al.  Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel , 2016, Molecules.

[2]  B. Sarmento,et al.  Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy. , 2015, Current drug targets.

[3]  Á. Tavares,et al.  Co‐silencing of human Bub3 and dynein highlights an antagonistic relationship in regulating kinetochore–microtubule attachments , 2015, FEBS letters.

[4]  A. Musacchio.  The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics , 2015, Current Biology.

[5]  H. Bousbaa,et al.  Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. , 2015, Oral diseases.

[6]  Yanchang Wang,et al.  The current view for the silencing of the spindle assembly checkpoint , 2014, Cell cycle.

[7]  Mark E. Burkard,et al.  Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles , 2014, Science Translational Medicine.

[8]  Stephen S. Taylor,et al.  Mitosis and apoptosis: how is the balance set? , 2013, Current opinion in cell biology.

[9]  T. Kapoor,et al.  Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore , 2012, Nature Reviews Molecular Cell Biology.

[10]  C. Koh,et al.  Mitosis-targeted anti-cancer therapies: where they stand , 2012, Cell Death and Disease.

[11]  B. Bennani-Baiti,et al.  Gene symbol precision. , 2012, Gene.

[12]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[13]  Stephen S. Taylor,et al.  p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit , 2011, Journal of Cell Science.

[14]  H. Bousbaa,et al.  Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint , 2011, Cell proliferation.

[15]  R. Medema,et al.  Mitosis as an anti-cancer target , 2011, Oncogene.

[16]  S. Geley,et al.  Spindly/CCDC99 Is Required for Efficient Chromosome Congression and Mitotic Checkpoint Regulation , 2010, Molecular biology of the cell.

[17]  K. Oegema,et al.  Removal of Spindly from microtubule-attached kinetochores controls spindle checkpoint silencing in human cells. , 2010, Genes & development.

[18]  W. V. van IJcken,et al.  Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction , 2010, PloS one.

[19]  R. Medema,et al.  Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells , 2009, Proceedings of the National Academy of Sciences.

[20]  T. Mitchison,et al.  Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. , 2009, Cancer cell.

[21]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[22]  Priti Kumar,et al.  Conditional RNAi: towards a silent gene therapy. , 2009, Advanced drug delivery reviews.

[23]  W. Taylor,et al.  Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit , 2009, Molecular Cancer Therapeutics.

[24]  D. Gerlich,et al.  Mitotic control of kinetochore-associated dynein and spindle orientation by human Spindly , 2009, The Journal of cell biology.

[25]  E. Salmon,et al.  Intrakinetochore stretch is associated with changes in kinetochore phosphorylation and spindle assembly checkpoint activity , 2009, The Journal of cell biology.

[26]  Christoph Bauer,et al.  Intrasession reliability of force platform parameters in community-dwelling older adults. , 2008, Archives of physical medicine and rehabilitation.

[27]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[28]  E. Eisenhauer,et al.  A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168) , 2008, Investigational New Drugs.

[29]  R. Vale,et al.  Spindly, a novel protein essential for silencing the spindle assembly checkpoint, recruits dynein to the kinetochore , 2007, The Journal of cell biology.

[30]  M. Kirschner,et al.  Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation , 2007, Nature.

[31]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[32]  G. Gorbsky,et al.  Spindle checkpoint function and cellular sensitivity to antimitotic drugs , 2006, Molecular Cancer Therapeutics.

[33]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[34]  Tomohiro Matsumoto,et al.  Low Concentrations of Taxol Cause Mitotic Delay Followed by Premature Dissociation of p55CDC from Mad2 and BubR1 and Abrogation of the Spindle checkpoint, Leading to Aneuploidy , 2005, Cell cycle.

[35]  Geert J P L Kops,et al.  Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Giaccone,et al.  Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  E. Salmon,et al.  Cytoplasmic dynein/dynactin drives kinetochore protein transport to the spindle poles and has a role in mitotic spindle checkpoint inactivation , 2001, The Journal of cell biology.

[38]  G. Chan,et al.  Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2 , 2001, The Journal of cell biology.

[39]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.